000162752 001__ 162752
000162752 005__ 20251017144621.0
000162752 0247_ $$2doi$$a10.1021/acsami.5c08968
000162752 0248_ $$2sideral$$a145322
000162752 037__ $$aART-2025-145322
000162752 041__ $$aeng
000162752 100__ $$aMattar, Iman
000162752 245__ $$aMultifunctional 3D-Printed Wound Dressings Containing a Combination of Synergistic Antimicrobials in the Management of MRSA Infected Topical Wounds
000162752 260__ $$c2025
000162752 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162752 5203_ $$aDespite increased pre- and postoperative care and aseptic practices in surgical rooms, methicillin-resistant Staphylococcus aureus (MRSA) continues to colonize acute surgical wounds. MRSA is also present in chronic nonhealing wounds, such as diabetic foot and pressure ulcers. In this work, advanced antimicrobial-loaded wound dressings are 3D printed using fused deposition modeling. To achieve a high antimicrobial effect, the topical antiseptic octenidine (OCT) was incorporated into the pellets used in the feeder of the extruder prior to fused modeling. Lysostaphin (LYS), a lytic enzyme that cleaves MRSA peptidoglycan, was incorporated by supramolecular interactions on the surface of the OCT-loaded dressings to exploit the anti-MRSA synergy identified here between OCT and LYS showing a fractional inhibition concentration index (FICI) of 0.156. Minimum inhibitory concentration (MIC) and bactericidal concentration (MBC) values for the OCT were 1 and 25 μg/mL, respectively, whereas the MIC and MBC values for the LYS were 0.1 and 0.2 μg/mL, respectively. The resulting dressings completely eradicate MRSA USA 300 inocula (105 CFU/mL) in 96 h. The bactericidal mechanisms exerted by these dressings were identified through molecular techniques, showing lytic effects on the cell wall peptidoglycans of treated bacteria. Additionally, OCT at 1 μg/mL was able to reduce lipopolysaccharide (100 ng/mL)-induced NO production on murine J774A.1 macrophages by more than 90% demonstrating its simultaneous anti-inflammatory action. This effect was also corroborated by the qRT-PCR analysis of several pro-inflammatory genes including IL-1β, IL-6, TNF-α, and Nos2. The combination of OCT and LYS within the dressings reveals higher in vivo therapeutic effects compared to free compounds or individual antimicrobial-loaded dressings. In vitro and in preclinical models, the use of OCT-LYS dressings effectively reduces MRSA bioburden and inflammation, promoting fast wound healing.
000162752 536__ $$9info:eu-repo/grantAgreement/ES/AEI/CEX2023-001286-S$$9info:eu-repo/grantAgreement/ES/ISCIII/FORT23-00028$$9info:eu-repo/grantAgreement/ES/ISCIII/MS19-00092$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-113987RB-I00$$9info:eu-repo/grantAgreement/ES/MICINN/PID2023-146091OB-I00$$9info:eu-repo/grantAgreement/ES/MICINN PRE2022-105709$$9info:eu-repo/grantAgreement/ES/UZ/LMA-ELECMI ICTS
000162752 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000162752 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162752 700__ $$0(orcid)0000-0003-1599-8216$$aLanda, Guillermo$$uUniversidad de Zaragoza
000162752 700__ $$aFrutos-Lizano, Marina
000162752 700__ $$aIzquierdo, Natalia
000162752 700__ $$aTapia, Elena$$uUniversidad de Zaragoza
000162752 700__ $$0(orcid)0000-0002-8133-2124$$aPerez, Marta$$uUniversidad de Zaragoza
000162752 700__ $$0(orcid)0000-0002-2053-9842$$aLujan, Lluis$$uUniversidad de Zaragoza
000162752 700__ $$0(orcid)0000-0002-2966-9088$$aIrusta, Silvia
000162752 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, Gracia
000162752 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, Manuel$$uUniversidad de Zaragoza
000162752 7102_ $$11001$$2025$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Anatom.Anatom.Patológ.Com
000162752 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000162752 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000162752 7102_ $$10$$2X$$aUniversidad de Zaragoza$$bS. Gral. Apoyo Investig. - SAI$$cServicios. División Biomédica
000162752 773__ $$g17, 34 (2025), 47951-47968$$pACS appl. mater. interfaces$$tACS applied materials & interfaces$$x1944-8244
000162752 8564_ $$s11245007$$uhttps://zaguan.unizar.es/record/162752/files/texto_completo.pdf$$yVersión publicada
000162752 8564_ $$s3299857$$uhttps://zaguan.unizar.es/record/162752/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162752 909CO $$ooai:zaguan.unizar.es:162752$$particulos$$pdriver
000162752 951__ $$a2025-10-17-14:22:02
000162752 980__ $$aARTICLE